GlobeNewsWire
12 Oct 2026, 21:45 UTC · 2h ago
Teva to Host R&D Day on Wednesday, November 11 in New York City
Impact · against what's priced in
Teva's upcoming R&D Day is a potential catalyst for long-term EPS revisions as the company provides specific details on its 5-year value-creation pipeline. While the overarching 'Pivot to Growth' strategy is known, the specific pipeline updates expected on November 11 represent new information that could drive valuation changes.
- TEVA+0.30
No priced-in read yet
- In context
The announcement of an R&D Day to detail the pipeline and value-creation potential over the next five years provides a concrete date for potential revisions to long-term growth estimates.
Read from the article alone
Search tags
